Organisation paid for research Program year 2023 Source: CMS Open Payments

Clinical Trials Source LLC

Neither a doctor nor a teaching hospital

Research payments

$3,135,353

102 payments

Through program year 2023, Clinical Trials Source LLC is reported as receiving $3,135,353 in research payments, across 102 payments.

By program year

3 rows
Year Kind Amount Payments
2023 Research $27,586 6
2022 Research $1,609,677 53
2021 Research $1,498,090 43

Breakdown

Who paid Research payments · program years 2021–2023
  1. Pfizer Inc. $3,117,564 91 payments
  2. AbbVie, Inc. $17,789 11 payments
Studies the money was for Research payments · program years 2021–2023
  1. A Phase 3 Study to Evaluate the Efficacy Immunogenicity and Safety of Respiratory Syncytial Virus RSV Prefusion F Subunit Vaccine in Adults $1,630,783 9 payments
  2. A Phase 23 Randomized Doubleblind Doubledummy Placebo Controlled Study to Evaluate the Safety and Efficacy of 2 Regimens of Orally Administered PF 07321332Ritonavir in Preventing Symptomatic Sarscov2 Infection in Adult Household Contacts of An Individual With Symptomatic Covid19 $486,864 22 payments
  3. A Phase 12 Randomized Study to Evaluate the Safety Tolerability and Immunogenicity of A Modified Rna Vaccine Against Influenza in Healthy Individuals $407,293 17 payments
  4. An Interventional Efficacy and Safety Phase 23 Doubleblind 2Arm Study to Investigate Orally Administered Pf07321332ritonavir Compared With Placebo in Nonhospitalized Symptomatic Adult Participants With Covid19 Who Are at Increased Risk of Progressing to Severe Illness $305,053 21 payments
  5. An Interventional Efficacy and Safety Phase 23 Doubleblind 2 Arm Study to Investigate Orally Administered PF 07321332Ritonavir Compared With Placebo in Nonhospitalized Symptomatic Adult Participants With Covid19 Who Are at Low Risk of Progressing to Severe Illness $287,570 22 payments
  6. A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) $17,642 10 payments
  7. A Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis (UC) $147 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2023

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record